Envoy Medical, Inc. (NASDAQ: COCH), a company specializing in hearing health and neuroprosthetics, announced on November 17, 2026, that it has been granted two additional patents in the United States and Hong Kong. These grants bring the company’s global patent portfolio to a total of 99 issued patents, with an additional 32 patent applications pending worldwide.
The newly granted U.S. Patent No. 12,773,553, titled "Cochlear Implant System with Electrode Impedance Diagnostics," covers technology related to the measurement and adjustment of electrode impedance within cochlear implant systems. Specifically, the patent describes a system capable of monitoring stimulation path impedance and compliance voltages, allowing the device to adjust the prescribed current when discrepancies arise between the expected and actual compliance voltages during stimulation.
In parallel, the Hong Kong Patent Office issued Hong Kong Patent No. HK40105814, entitled "Cochlear Implant System with Integrated Signal Analysis Functionality." This patent protects methods involving the use of an external device to receive representative signals from a fully implantable cochlear implant system, analyze those signals, and output a corresponding representation. This capability facilitates enhanced monitoring and diagnostic functions for the implant system.
Envoy Medical’s intellectual property portfolio now includes 41 U.S. patents and 58 foreign patents, with 24 foreign and eight U.S. patent applications pending. The portfolio encompasses a broad range of technologies underpinning the company’s fully implanted hearing platform, including sensing, signal processing, implantation techniques, and system integration.
The company’s patent strategy also accounts for European patents, distinguishing between European Patent Office grants and their validations or unitary patent statuses in individual countries.
Envoy Medical is recognized for its pioneering work in fully implanted hearing devices. Its Esteem® active middle ear implant has been commercially available in the United States since 2010. The company is currently advancing the Acclaim® cochlear implant, a fully implanted device designed to address severe to profound sensorineural hearing loss that is inadequately managed by conventional hearing aids.
The Acclaim Cochlear Implant incorporates a novel sensor that leverages the ear’s natural anatomy to capture sound, rather than relying on an external microphone. This device received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019 and is presently undergoing a pivotal clinical trial in the United States.
Envoy Medical’s continued expansion of its intellectual property portfolio underscores its commitment to advancing hearing technology and improving patient outcomes through innovative, fully implanted solutions.
For further information or to join Envoy Medical’s email distribution list, interested parties may contact Envoy@kcsa.com with "COCH" in the subject line.
More details on the Acclaim pivotal clinical trial are available at www.envoymedical.com/acclaim-pivotal.
Envoy Medical Secures Two New Patents for Advanced Cochlear Implant Diagnostics and Signal Analysis Envoy Medical, a pioneer in fully implanted hearing devices, has expanded its patent portfolio with two new grants: U.S. Patent No. 12,773,553 for cochlear implant electrode impedance diagnostics and Hong Kong Patent No... Read the full IIPLA article: https://iipla.org/news/envoy-medical-secures-two-new-patents-for-advanced-cochlear-implant-diagnostics-and-signal-analysis